發(fā)布時(shí)間：2018-02-16 22:28

  本文關(guān)鍵詞： 晚期非小細(xì)胞肺癌 血清miRNA 中西醫(yī)聯(lián)合　出處：《中國(guó)中西醫(yī)結(jié)合雜志》2016年09期 　論文類(lèi)型：期刊論文

【摘要】：目的對(duì)中西醫(yī)聯(lián)合治療晚期非小細(xì)胞肺癌(NSCLC)獲益血清miRNA表達(dá)譜進(jìn)行初步研究,探討晚期NSCLC療效監(jiān)測(cè)和預(yù)測(cè)分子標(biāo)記物。方法選取5例接受中西醫(yī)聯(lián)合治療且療效獲益的晚期NSCLC患者(簡(jiǎn)稱(chēng)治療組)和3例晚期NSCLC初治患者(簡(jiǎn)稱(chēng)肺癌組)及3名健康體檢者(簡(jiǎn)稱(chēng)對(duì)照組),采集血清標(biāo)本并用Trizol法提取總RNA,運(yùn)用Exiqon公司microRNA PCR ARRAY芯片技術(shù)篩選檢測(cè)肺癌組血清與對(duì)照組血清中差異miRNA表達(dá)譜、治療組血清與肺癌組血清差異miRNA表達(dá)譜,基于聚類(lèi)分析及對(duì)比分析,進(jìn)一步得到中西醫(yī)聯(lián)合治療晚期NSCLC獲益miRNA表達(dá)譜。結(jié)果經(jīng)microRNA PCR ARRAY檢測(cè)和數(shù)據(jù)分析處理后,肺癌組與對(duì)照組共篩選出42個(gè)差異在2倍以上的miRNAs,其中29個(gè)為上調(diào)的miRNAs,13個(gè)為下調(diào)的miRNAs;且miR-10b-5p、miR-21-5p、miR-182-5p、miR-361-3p、miR-382-5p差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療組與肺癌組篩選出45個(gè)差異在2倍以上的miRNAs,其中12個(gè)上調(diào)的miRNAs,33個(gè)下調(diào)的miRNAs;miR-137-3p、miR-182-5p、miR-376a-3p、miR-382-5p、miR-409-3p、miR-10a-5p、miR-21-5p、miR-29a-3p、miR-141-3p、miR-150-5p、miR-200c-3p、miR-342-3p、miR-365a-3p、miR-375、miR-502-3p 15個(gè)miRNAs差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療組與肺癌組差異倍數(shù)2倍,與對(duì)照組差異倍數(shù)≤2倍的血清miRNA共篩選出22個(gè),其中7個(gè)為上調(diào)miRNAs,15個(gè)為下調(diào)miRNAs;miR-127-3p、miR-182-5p、miR-382-5p、miR-409-3p、miR-10a-5p、miR-21-5p、miR-141-3p、miR-342-3p 8個(gè)miRNAs差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論包括miR-21-5p、miR-182-5p、miR-382-5p在內(nèi)的差異miRNAs有望成為中西醫(yī)聯(lián)合治療晚期NSCLC療效監(jiān)測(cè)和預(yù)測(cè)分子標(biāo)記物;為中西醫(yī)聯(lián)合治療晚期NSCLC個(gè)體化治療提供參考。
[Abstract]:Objective to study the expression profile of serum miRNA in patients with advanced non-small cell lung cancer (NSCLC) treated with combination of traditional Chinese and western medicine. To explore the molecular markers for monitoring and predicting the efficacy of advanced NSCLC. Methods five patients with advanced NSCLC who received combined traditional Chinese and Western medicine therapy and three patients with advanced NSCLC were selected as control group and 3 patients with lung cancer. Serum samples were collected from healthy controls and total RNAs were extracted by Trizol method. The differential miRNA expression profiles in serum of lung cancer group and control group were detected by microRNA PCR ARRAY chip technique of Exiqon company. The differential miRNA expression profile in serum of treatment group and lung cancer group was further obtained based on cluster analysis and comparative analysis. Results after microRNA PCR ARRAY detection and data analysis, the miRNA expression profile of NSCLC was obtained in the late stage of treatment with combination of traditional Chinese and western medicine. A total of 42 miRNAss of lung cancer group and control group were screened out, of which 29 were upregulated miRNAss and 13 were down-regulated miRNAss, and there were significant differences in miR-182-5ptimiR-361-3ptimiR-382-5P between the treatment group and the lung cancer group, and 45 miRNAss with a difference of more than 2 times were screened between the treatment group and the lung cancer group. Twelve of the upregulated miRNAss, and 33 down-regulated miR-137-3phe miR-182-5 pnmiR-376a-3pnmiR-382-5pmiR-409-3 pnmiR-10a-5pnmiR-29a-3pmiR-141-3pmiR-150-5pmiR-3pmiR-342-3pmiR-365a-3pnmiR-375miR-502-3p, have statistical significance. The difference between the treatment group and the lung cancer group is 2 times higher than that of the lung cancer group, and the difference between the treatment group and the lung cancer group is 2 times higher than that of the control group. A total of 22 serum miRNA with a difference of 鈮，

本文編號(hào)：1516578